JP2022512922A - キメラ抗原受容体記憶様(carml)nk細胞ならびにその産生および使用方法 - Google Patents
キメラ抗原受容体記憶様(carml)nk細胞ならびにその産生および使用方法 Download PDFInfo
- Publication number
- JP2022512922A JP2022512922A JP2021524069A JP2021524069A JP2022512922A JP 2022512922 A JP2022512922 A JP 2022512922A JP 2021524069 A JP2021524069 A JP 2021524069A JP 2021524069 A JP2021524069 A JP 2021524069A JP 2022512922 A JP2022512922 A JP 2022512922A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- cells
- car
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000822 natural killer cell Anatomy 0.000 title claims abstract description 257
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title claims abstract description 149
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 90
- 210000004027 cell Anatomy 0.000 claims description 97
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 94
- 206010028980 Neoplasm Diseases 0.000 claims description 85
- 239000000427 antigen Substances 0.000 claims description 70
- 108091007433 antigens Proteins 0.000 claims description 70
- 102000036639 antigens Human genes 0.000 claims description 70
- 201000010099 disease Diseases 0.000 claims description 70
- 238000011282 treatment Methods 0.000 claims description 38
- 201000011510 cancer Diseases 0.000 claims description 32
- 230000004068 intracellular signaling Effects 0.000 claims description 31
- 102000004127 Cytokines Human genes 0.000 claims description 29
- 108090000695 Cytokines Proteins 0.000 claims description 29
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 21
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 21
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 20
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 20
- 208000015181 infectious disease Diseases 0.000 claims description 19
- 230000008685 targeting Effects 0.000 claims description 19
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 claims description 17
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 claims description 17
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 claims description 15
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 15
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 15
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 claims description 15
- 102000006495 integrins Human genes 0.000 claims description 15
- 108010044426 integrins Proteins 0.000 claims description 15
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims description 14
- 241000713666 Lentivirus Species 0.000 claims description 14
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims description 14
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 14
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims description 14
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims description 14
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims description 14
- 241000700605 Viruses Species 0.000 claims description 14
- 208000035473 Communicable disease Diseases 0.000 claims description 12
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims description 12
- 102100029198 SLAM family member 7 Human genes 0.000 claims description 12
- 230000004044 response Effects 0.000 claims description 12
- 102100038077 CD226 antigen Human genes 0.000 claims description 11
- 102100027207 CD27 antigen Human genes 0.000 claims description 11
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 claims description 11
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 11
- 102100020790 Interleukin-12 receptor subunit beta-1 Human genes 0.000 claims description 11
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 11
- 230000001363 autoimmune Effects 0.000 claims description 11
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 claims description 10
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 claims description 10
- -1 actKIR Proteins 0.000 claims description 10
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 10
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 10
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 10
- 102100030013 Endoribonuclease Human genes 0.000 claims description 9
- 101710199605 Endoribonuclease Proteins 0.000 claims description 9
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims description 9
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims description 9
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 claims description 9
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 claims description 9
- 102100025304 Integrin beta-1 Human genes 0.000 claims description 9
- 102100025390 Integrin beta-2 Human genes 0.000 claims description 9
- 102100032999 Integrin beta-3 Human genes 0.000 claims description 9
- 102100029197 SLAM family member 6 Human genes 0.000 claims description 9
- 238000010361 transduction Methods 0.000 claims description 9
- 230000026683 transduction Effects 0.000 claims description 9
- 239000013603 viral vector Substances 0.000 claims description 9
- 208000026278 immune system disease Diseases 0.000 claims description 8
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 8
- 239000013598 vector Substances 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 7
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims description 7
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims description 7
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims description 7
- 101710090322 Truncated surface protein Proteins 0.000 claims description 7
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 7
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 claims description 6
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 claims description 6
- 101001003142 Homo sapiens Interleukin-12 receptor subunit beta-1 Proteins 0.000 claims description 6
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 claims description 6
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 108040002039 interleukin-15 receptor activity proteins Proteins 0.000 claims description 6
- 102000008616 interleukin-15 receptor activity proteins Human genes 0.000 claims description 6
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 5
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 5
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 5
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 5
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 5
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 5
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 5
- 101001055145 Homo sapiens Interleukin-2 receptor subunit beta Proteins 0.000 claims description 5
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 5
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 5
- 102100026879 Interleukin-2 receptor subunit beta Human genes 0.000 claims description 5
- 108010017411 Interleukin-21 Receptors Proteins 0.000 claims description 5
- 102100030699 Interleukin-21 receptor Human genes 0.000 claims description 5
- 102000003735 Mesothelin Human genes 0.000 claims description 5
- 108090000015 Mesothelin Proteins 0.000 claims description 5
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 5
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 5
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims description 5
- 101710178300 Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 5
- 108040003610 interleukin-12 receptor activity proteins Proteins 0.000 claims description 5
- 108040002014 interleukin-18 receptor activity proteins Proteins 0.000 claims description 5
- 102000008625 interleukin-18 receptor activity proteins Human genes 0.000 claims description 5
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 4
- 229920000209 Hexadimethrine bromide Polymers 0.000 claims description 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 4
- 101100232351 Homo sapiens IL12RB1 gene Proteins 0.000 claims description 4
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims description 4
- 230000002489 hematologic effect Effects 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 76
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 description 90
- 239000003814 drug Substances 0.000 description 35
- 239000000203 mixture Substances 0.000 description 33
- 229940079593 drug Drugs 0.000 description 31
- 150000007523 nucleic acids Chemical class 0.000 description 31
- 108020004707 nucleic acids Proteins 0.000 description 25
- 102000039446 nucleic acids Human genes 0.000 description 25
- 108090000623 proteins and genes Proteins 0.000 description 25
- 208000035475 disorder Diseases 0.000 description 22
- 239000003795 chemical substances by application Substances 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 17
- 208000011580 syndromic disease Diseases 0.000 description 17
- 230000006870 function Effects 0.000 description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 description 13
- 206010039491 Sarcoma Diseases 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 12
- 230000002688 persistence Effects 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 206010025323 Lymphomas Diseases 0.000 description 11
- 230000004913 activation Effects 0.000 description 11
- 238000001994 activation Methods 0.000 description 11
- 102000003675 cytokine receptors Human genes 0.000 description 11
- 108010057085 cytokine receptors Proteins 0.000 description 11
- 239000005090 green fluorescent protein Substances 0.000 description 11
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 10
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 10
- 108020004459 Small interfering RNA Proteins 0.000 description 10
- 238000013461 design Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000003834 intracellular effect Effects 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 239000004055 small Interfering RNA Substances 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 208000003174 Brain Neoplasms Diseases 0.000 description 9
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 239000003242 anti bacterial agent Substances 0.000 description 8
- 102100037850 Interferon gamma Human genes 0.000 description 7
- 108010074328 Interferon-gamma Proteins 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 230000011664 signaling Effects 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 206010037660 Pyrexia Diseases 0.000 description 6
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 6
- 238000013270 controlled release Methods 0.000 description 6
- 210000002308 embryonic cell Anatomy 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 5
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 description 5
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 5
- 230000000735 allogeneic effect Effects 0.000 description 5
- 229940121363 anti-inflammatory agent Drugs 0.000 description 5
- 239000002260 anti-inflammatory agent Substances 0.000 description 5
- 230000005784 autoimmunity Effects 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 201000003444 follicular lymphoma Diseases 0.000 description 5
- 230000009368 gene silencing by RNA Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 201000008968 osteosarcoma Diseases 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 125000006850 spacer group Chemical group 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 5
- 206010005949 Bone cancer Diseases 0.000 description 4
- 208000018084 Bone neoplasm Diseases 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 206010010356 Congenital anomaly Diseases 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 208000003445 Mouth Neoplasms Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 238000004422 calculation algorithm Methods 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 208000031513 cyst Diseases 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000022120 response to tumor cell Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 206010004593 Bile duct cancer Diseases 0.000 description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 3
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 208000006168 Ewing Sarcoma Diseases 0.000 description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010061252 Intraocular melanoma Diseases 0.000 description 3
- 101150069255 KLRC1 gene Proteins 0.000 description 3
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
- 230000006051 NK cell activation Effects 0.000 description 3
- 206010040070 Septic Shock Diseases 0.000 description 3
- 108091027967 Small hairpin RNA Proteins 0.000 description 3
- 206010044248 Toxic shock syndrome Diseases 0.000 description 3
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 3
- 108700009124 Transcription Initiation Site Proteins 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 201000005969 Uveal melanoma Diseases 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 230000006023 anti-tumor response Effects 0.000 description 3
- 238000002617 apheresis Methods 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 208000026900 bile duct neoplasm Diseases 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 208000006990 cholangiocarcinoma Diseases 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 230000008622 extracellular signaling Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000012239 gene modification Methods 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 102000008640 interleukin-21 receptor activity proteins Human genes 0.000 description 3
- 108040002099 interleukin-21 receptor activity proteins Proteins 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 206010025135 lupus erythematosus Diseases 0.000 description 3
- 206010065579 multifocal motor neuropathy Diseases 0.000 description 3
- 201000002575 ocular melanoma Diseases 0.000 description 3
- 238000007427 paired t-test Methods 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 201000008827 tuberculosis Diseases 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000008190 Agammaglobulinemia Diseases 0.000 description 2
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- 208000021866 Dressler syndrome Diseases 0.000 description 2
- 206010014909 Enterovirus infection Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- 206010016207 Familial Mediterranean fever Diseases 0.000 description 2
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 2
- 208000010235 Food Addiction Diseases 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 208000005577 Gastroenteritis Diseases 0.000 description 2
- 208000007465 Giant cell arteritis Diseases 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102100033945 Glycine receptor subunit alpha-1 Human genes 0.000 description 2
- 206010018691 Granuloma Diseases 0.000 description 2
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 2
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 101000996297 Homo sapiens Glycine receptor subunit alpha-1 Proteins 0.000 description 2
- 101001109508 Homo sapiens NKG2-A/NKG2-B type II integral membrane protein Proteins 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 2
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 2
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 2
- 208000031814 IgA Vasculitis Diseases 0.000 description 2
- 208000028622 Immune thrombocytopenia Diseases 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 208000005615 Interstitial Cystitis Diseases 0.000 description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- 208000012309 Linear IgA disease Diseases 0.000 description 2
- 208000004852 Lung Injury Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 201000004458 Myoma Diseases 0.000 description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 208000010505 Nose Neoplasms Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 201000005702 Pertussis Diseases 0.000 description 2
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 2
- 206010034811 Pharyngeal cancer Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 2
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010041925 Staphylococcal infections Diseases 0.000 description 2
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 2
- 206010042276 Subacute endocarditis Diseases 0.000 description 2
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 206010057644 Testis cancer Diseases 0.000 description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
- 235000011941 Tilia x europaea Nutrition 0.000 description 2
- 206010069363 Traumatic lung injury Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 241000607598 Vibrio Species 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 208000010396 acute flaccid myelitis Diseases 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 239000000611 antibody drug conjugate Substances 0.000 description 2
- 229940049595 antibody-drug conjugate Drugs 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 208000035269 cancer or benign tumor Diseases 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 201000007455 central nervous system cancer Diseases 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 201000000708 eosinophilic esophagitis Diseases 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 201000000284 histiocytoma Diseases 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 201000006866 hypopharynx cancer Diseases 0.000 description 2
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000001821 langerhans cell Anatomy 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000004571 lime Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 231100000515 lung injury Toxicity 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000036244 malformation Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 206010063344 microscopic polyangiitis Diseases 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 208000037830 nasal cancer Diseases 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000001769 paralizing effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 208000008467 subacute bacterial endocarditis Diseases 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 206010043207 temporal arteritis Diseases 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 208000037965 uterine sarcoma Diseases 0.000 description 2
- 206010055031 vascular neoplasm Diseases 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 241000004176 Alphacoronavirus Species 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 241000606646 Anaplasma Species 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010031480 Artificial Receptors Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 206010064539 Autoimmune myocarditis Diseases 0.000 description 1
- 206010069002 Autoimmune pancreatitis Diseases 0.000 description 1
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 1
- 208000022106 Autoimmune polyendocrinopathy type 2 Diseases 0.000 description 1
- 208000011594 Autoinflammatory disease Diseases 0.000 description 1
- 206010061666 Autonomic neuropathy Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 241000223836 Babesia Species 0.000 description 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 108010017316 CCR3 Receptors Proteins 0.000 description 1
- 102000004499 CCR3 Receptors Human genes 0.000 description 1
- 201000002829 CREST Syndrome Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 201000000724 Chronic recurrent multifocal osteomyelitis Diseases 0.000 description 1
- 241000223203 Coccidioides Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 208000010007 Cogan syndrome Diseases 0.000 description 1
- 208000011038 Cold agglutinin disease Diseases 0.000 description 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010011258 Coxsackie myocarditis Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
- 241000223935 Cryptosporidium Species 0.000 description 1
- 208000011917 Cyclosporosis Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241001475178 Dira Species 0.000 description 1
- 208000010772 Dog disease Diseases 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 244000148064 Enicostema verticillatum Species 0.000 description 1
- 206010014961 Eosinophilic myocarditis Diseases 0.000 description 1
- 208000006536 Ephemeral Fever Diseases 0.000 description 1
- 108050004280 Epsilon toxin Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
- 206010061126 Escherichia infection Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000004332 Evans syndrome Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 206010019263 Heart block congenital Diseases 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 101001003138 Homo sapiens Interleukin-12 receptor subunit beta-2 Proteins 0.000 description 1
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 description 1
- 101000945342 Homo sapiens Killer cell immunoglobulin-like receptor 2DS4 Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 208000021330 IgG4-related disease Diseases 0.000 description 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000031781 Immunoglobulin G4 related sclerosing disease Diseases 0.000 description 1
- 208000004187 Immunoglobulin G4-Related Disease Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 208000027601 Inner ear disease Diseases 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 102100020792 Interleukin-12 receptor subunit beta-2 Human genes 0.000 description 1
- 108010052781 Interleukin-3 Receptor alpha Subunit Proteins 0.000 description 1
- 102000018883 Interleukin-3 Receptor alpha Subunit Human genes 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 1
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
- 101150069380 JAK3 gene Proteins 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 108010043610 KIR Receptors Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- 102100033624 Killer cell immunoglobulin-like receptor 2DS4 Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010062038 Lip neoplasm Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
- 208000004059 Male Breast Neoplasms Diseases 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- 206010028570 Myelopathy Diseases 0.000 description 1
- 206010028780 Nasal ulcer Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
- 206010029379 Neutrophilia Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 241001263478 Norovirus Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 206010058461 Orchitis noninfective Diseases 0.000 description 1
- 241000150452 Orthohantavirus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000025174 PANDAS Diseases 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 206010053869 POEMS syndrome Diseases 0.000 description 1
- 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000008223 Pemphigoid Gestationis Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 208000035109 Pneumococcal Infections Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 201000008183 Pulmonary blastoma Diseases 0.000 description 1
- 206010037688 Q fever Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010038111 Recurrent cancer Diseases 0.000 description 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 description 1
- 102000005886 STAT4 Transcription Factor Human genes 0.000 description 1
- 108010019992 STAT4 Transcription Factor Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010079723 Shiga Toxin Proteins 0.000 description 1
- 108010029157 Sialic Acid Binding Ig-like Lectin 2 Proteins 0.000 description 1
- 102000001613 Sialic Acid Binding Ig-like Lectin 2 Human genes 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 241000251131 Sphyrna Species 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 241000224526 Trichomonas Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108010080432 Tumor Necrosis Factor Receptor-Associated Peptides and Proteins Proteins 0.000 description 1
- 102000000160 Tumor Necrosis Factor Receptor-Associated Peptides and Proteins Human genes 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 208000028227 Viral hemorrhagic fever Diseases 0.000 description 1
- 208000025749 Vogt-Koyanagi-Harada disease Diseases 0.000 description 1
- 208000034705 Vogt-Koyanagi-Harada syndrome Diseases 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000719 anti-leukaemic effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 201000009780 autoimmune polyendocrine syndrome type 2 Diseases 0.000 description 1
- 206010071578 autoimmune retinopathy Diseases 0.000 description 1
- 208000029407 autoimmune urticaria Diseases 0.000 description 1
- 201000008680 babesiosis Diseases 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 150000001639 boron compounds Chemical class 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 208000025997 central nervous system neoplasm Diseases 0.000 description 1
- 201000004559 cerebral degeneration Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
- 208000024376 chronic urticaria Diseases 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 201000003486 coccidioidomycosis Diseases 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 201000004395 congenital heart block Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 201000002641 cyclosporiasis Diseases 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 201000011523 endocrine gland cancer Diseases 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 208000003401 eosinophilic granuloma Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 208000020612 escherichia coli infection Diseases 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000000646 extraembryonic cell Anatomy 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 208000018090 giant cell myocarditis Diseases 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 201000010284 hepatitis E Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000056003 human IL15 Human genes 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000005746 immune checkpoint blockade Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 208000033353 latent tuberculosis infection Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 201000006721 lip cancer Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 201000003175 male breast cancer Diseases 0.000 description 1
- 208000010907 male breast carcinoma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 208000005871 monkeypox Diseases 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 208000029522 neoplastic syndrome Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 208000008795 neuromyelitis optica Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000021010 pancreatic neuroendocrine tumor Diseases 0.000 description 1
- 208000007312 paraganglioma Diseases 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 208000010626 plasma cell neoplasm Diseases 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000037968 sinus cancer Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 206010062261 spinal cord neoplasm Diseases 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000004500 stellate cell Anatomy 0.000 description 1
- 208000026082 sterile multifocal osteomyelitis with periostitis and pustulosis Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008359 toxicosis Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 208000009174 transverse myelitis Diseases 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013464 vaginal disease Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001112—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464413—CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464419—Receptors for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
本出願は、2018年11月6日出願の米国仮出願62/756,294および2019年1月4日出願の米国仮出願62/788,440に基づく優先権を主張し、これらは、引用によりその全体として本明細書に包含させる。
適用なし。
本開示の一部である配列表は、本発明のヌクレオチドおよび/またはアミノ酸配列を含むコンピュータ読み取り可能形式を含む。配列表の主題は、引用によりその全体として本明細書に包含させる。
本発明は、一般に修飾NK細胞に関する。
本発明の種々の態様の一つは、記憶様キメラ抗原受容体(CARML)NK細胞およびその使用方法の提供である。
本発明は、少なくとも部分的に、合成生物学またはゲノム編集を介する、ML NK細胞における使用に適するCARを取り込む記憶様(ML)NK細胞の修飾が、広範囲の標的(例えば、腫瘍、自己抗体)を認識させその機能、生存または持続を増強させ得るとの発見に基づく。本発明は、NK細胞、より具体的に、ML NK細胞に取り込まれることができる、これらのCAR構築物の設計を初めて公開するものであると考える。これらのCARML NK細胞構築物は、癌(例えば、癌免疫療法)または免疫関連または自己免疫疾患の処置に使用され得る。
ナチュラルキラー(NK)細胞は、感染および癌に対して最前線で働く細胞毒性先天性リンパ系細胞である。炎症性微小環境で、複数の可溶性および接触依存的シグナルがNK細胞反応性を調節する。その先天的細胞毒性および免疫刺激性活性に加えて、最近、NK細胞が異種および万能細胞サブセットを構成することが発見された。強固なリコール応答を搭載する永続性記憶様NK集団がウイルス感染、接触過敏症反応中および炎症性促進性サイトカインまたは活性化受容体経路での刺激後に報告されている。
本発明は、CARで修飾されたML NK細胞を提供する。本発明は、NK細胞、より具体的に、ML NK細胞に取り込まれることができるこれらのCAR構築物を初めて設計設計したと考える。
疾患関連抗原に対するターゲティング抗体フラグメントは、一本鎖可変フラグメント(scFv)を含み得る。ここに記載するとおり、scFvは標的抗原または標的抗原エピトープに結合できるあらゆるscFvであり得る。例えば、scFvは、感染性疾患、細菌感染、ウイルスまたは癌と関連する抗原を標的できる。scFvは、米国出願15/179,472に記載され、引用により全体として本明細書に包含させるもののような、当分野で知られるあらゆる抗原に対してであり得る。
抗CD19 scFv(配列番号1)
ATGGCCCTGCCCGTGACCGCTCTCCTGCTGCCTCTGGCCCTGCTCCTCCATGCTGCCAGACCCGACATCCAGATGACACAGACAACCAGCAGCCTGTCCGCTTCCCTCGGAGACAGGGTGACAATTTCCTGCAGGGCCAGCCAGGACATCAGCAAGTACCTGAACTGGTACCAGCAGAAACCCGACGGCACCGTCAAGCTCCTGATCTACCACACCAGCAGACTGCACAGCGGAGTGCCTTCCAGGTTCAGCGGCAGCGGCTCCGGCACCGATTACTCCCTGACCATTAGCAACTTAGAACAGGAGGACATTGCCACCTACTTTTGTCAGCAGGGCAACACCCTCCCCTACACCTTTGGAGGCGGAACCAAGTTAGAAATCACCGGCGGCGGCGGCAGCGGAGGAGGAGGCAGCGGAGGCGGAGGCTCCGAGGTGAAACTGCAGGAGAGCGGCCCCGGACTGGTCGCCCCTAGCCAATCCCTCTCCGTCACCTGCACCGTGAGCGGAGTGAGCCTGCCTGACTACGGAGTGAGCTGGATCAGACAGCCCCCTAGGAAAGGACTGGAATGGCTGGGCGTGATTTGGGGCAGCGAGACCACCTATTACAACAGCGCCCTGAAGTCCAGACTGACAATCATCAAGGACAATAGCAAAAGCCAAGTGTTTCTGAAGATGAACAGCCTGCAGACCGATGACACCGCCATCTATTATTGCGCCAAGCACTACTACTACGGAGGAAGCTACGCTATGGATTATTGGGGCCAAGGCACAAGCGTGACCGTCAGCAGCGCGGCCGCC
ATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGATGGAAAAGGATACACTGTTGTTGTGGGTTCTGCTCCTGTGGGTGCCCGGCAGCACCGGAGATATTGTGCTGACGCAGTCTCCTGCATCACTCGCCGTGTCTCTGGGCCAGCGCGCTACCATCAGCTGCAGAGCCTCTGAAAGTGTTGACAATTATGGAATTTCTTTCATGAATTGGTTCCAGCAGAAGCCTGGCCAGCCCCCGAAACTCCTCATATATGCCGCGTCTAATCAGGGCTCTGGGGTCCCTGCTAGATTTTCTGGCAGCGGCTCCGGCACCGACTTCAGTCTGAATATACATCCCATGGAAGAAGACGATACCGCCATGTACTTTTGCCAACAATCTAAGGAGGTGCCTTGGACGTTCGGCGGCGGTACGAAGCTGGAAATTAAGGGCGGCGGGGGAAGCGGCGGGGGGGGATCAGGCGGGGGTGGCTCCGGAGGCGGTGGAAGTATGGGCTGGAGTTGGATCTTCCTTTTCCTTCTTTCTGGTACCGCGGGAGTGCACTCTGAGGTGCAGCTCCAGCAGTCCGGCCCCGAGCTCGTCAAGCCTGGGGCCAGTGTCAAGATTTCCTGTAAGGCATCTGGATATACCTTTACAGATTACAATATGCATTGGGTGAAACAGTCACATGGAAAGTCACTCGAGTGGATCGGATACATTTACCCTTACAATGGAGGAACCGGATATAATCAGAAGTTTAAGAGCAAGGCCACACTCACGGTGGACAATTCTTCATCTACAGCCTACATGGATGTTCGGTCTCTGACTTCCGAGGATAGTGCGGTGTATTACTGCGCCAGGGGACGCCCCGCTATGGATTACTGGGGGCAGGGAACCTCTGTAACAGTTAGCTCA
ATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGACTTCGTGATGACTCAGTCTCCTAGCTCCCTGACCGTGACAGCCGGCGAGAAGGTGACCATGTCCTGCAAATCTAGTCAGAGTCTGCTGAACTCAGGCAATCAGAAGAACTATCTGACATGGTACCTGCAGAAGCCAGGGCAGCCCCCTAAACTGCTGATCTATTGGGCCAGCACCAGGGAATCCGGCGTGCCCGACAGATTCACCGGCTCCGGGTCTGGAACAGATTTTACTCTGACCATTTCAAGCGTGCAGGCCGAGGACCTGGCTGTGTACTATTGTCAGAATGATTACAGCTATCCCTACACATTTGGCGGGGGAACTAAGCTGGAAATCAAAGGTGGTGGTGGTTCTGGTGGTGGTGGTTCCGGCGGCGGCGGCTCCGGTGGTGGTGGATCCGAGGTGCAGCTGCAGCAGAGTGGACCCGAACTGGTGAAACCTGGCGCCTCCGTGAAAATGTCTTGCAAGGCTAGTGGGTACACCTTCACAGACTACTATATGAAATGGGTGAAGCAGTCACACGGGAAGAGCCTGGAGTGGATCGGAGATATCATTCCCTCTAACGGCGCCACTTTCTACAATCAGAAGTTTAAAGGCAAGGCTACTCTGACCGTGGACCGGAGCTCCTCTACCGCCTATATGCACCTGAACAGTCTGACATCAGAAGATAGCGCTGTGTACTATTGTACACGGTCCCATCTGCTGAGAGCCTCTTGGTTTGCTTATTGGGGCCAGGGGACACTGGTGACTGTGAGCTCCGCTAGCACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATTTTTGGGTGCTGGTGGTGGTTGGTGGAGTCCTGGCTTGCTATAGCTTGCTAGTAACAGTGGCCTTTATTATTTTCTGGGTG
ここに記載する構築物は、細胞膜にまたがる疎水性α螺旋からなる膜貫通ドメインを含む。膜貫通ドメインの主機能はML NK細胞膜にCARを固定することであるが、以前の証拠は、膜貫通ドメインがCAR細胞機能に関連し得ることも示唆する。
スペーサーとも称するヒンジは、結合単位を膜貫通ドメインと離す、CARの細胞外構造領域である。ヒンジは、CARML NK細胞の標的への近接を確実にし得るあらゆる部分であり得る(例えば、NKG2ベースのヒンジ、TMαベースのヒンジ、CD8ベースのヒンジ)。NKG2Dなどの受容体の細胞外部分全体に基づくいくつかのCARを例外として、ここに記載するとおり、CAR(例えばCAR T)細胞の大部分は、免疫グロブリン(Ig)様ドメインヒンジを用いて設計される。
NKG2D(ヒンジ(配列番号4)/TM(配列番号5))
TCCACAAGAATCAAGATCTTCCCTCTCTGAGCAGGAATCCTTTGTGCATTGAAGACTTTAGATTCCTCTCTGCGGTAGACGTGCACTTATAAGTATTTGATGGGGTGGATTCGTGGTCGGAGGTCTCGACACAGCTGGGAGATGAGTGAATTTCATAATTATAACTTGGATCTGAAGAAGAGTGATTTTTCAACACGATGGCAAAAGCAAAGATGTCCAGTAGTCAAAAGCAAATGTAGAGAAAATGCATCT/CCATTTTTTTTCTGCTGCTTCATCGCTGTAGCCATGGGAATCCGTTTCATTATTATGGTAACAATATGGAGT
CACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACATATTTACAGAATGGCAAAGGCAGGAAGTATTTTCATCATAATTCTGACTTCTACATTCCAAAAGCCACACTCAAAGACAGCGGCTCCTACTTCTGCAGGGGGCTTTTTGGGAGTAAAAATGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCATCATTCTTTCCACCTGGGTACCAA/GTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCAGTGGACACAGGACTATATTTCTCTGTGAAGACAAACA
TGTAGAATCTACCGCCCTTCTGACAACTCTGTCTCTAAGTCCGTCAGATTCTATCTGGTGGTATCTCCAGCCTCTGCCTCCACACAGACCTCCTGGACTCCCCGCGACCTGGTCTCTTCACAGACCCAGACCCAGAGCTGTGTGCCTCCCACTGCAGGAGCCAGACAAGCCCCTGAGTCTCCATCTACCATCCCTGTCCCTTCACAGCCACAGAACTCCACGCTCCGCCCTGGCCCTGCAGCCCCCATTGCC/CTGGTGCCTGTGTTCTGTGGACTCCTCGTAGCCAAGAGCCTGGTGCTGTCAGCCCTGCTCGTCTGGTGGGGG
TCCGTCACGTGGTTCCGAGATGAGGTGGTTCCAGGGAAGGAGGTGAGGAATGGAACCCCAGAGTTCAGGGGCCGCCTGGCCCCACTTGCTTCTTCCCGTTTCCTCCATGACCACCAGGCTGAGCTGCACATCCGGGACGTGCGAGGCCATGACGCCAGCATCTACGTGTGCAGAGTGGAGGTGCTGGGCCTTGGTGTCGGGACAGGGAATGGGACTCGGCTGGTGGTGGAGAAAGAACATCCTCAGCTAGGG/GCTGGTACAGTCCTCCTCCTTCGGGCTGGATTCTATGCTGTCAGCTTTCTCTCTGTGGCCGTGGGCAGCACC
TTCCCCCTGGGCCCTGTGACCACAGCCCACAGAGGGACATACCGATGTTTTGGCTCCTATAACAACCATGCCTGGTCTTTCCCCAGTGAGCCAGTGAAGCTCCTGGTCACAGGCGACATTGAGAACACCAGCCTTGCACCTGAAGACCCCACCTTTCCTGCAGACACTTGGGGCACCTACCTTTTAACCACAGAGACGGGACTCCAGAAAGACCATGCCCTCTGGGATCACACTGCCCAGAATCTCCTTCGG/ATGGGCCTGGCCTTTCTAGTCCTGGTGGCTCTAGTGTGGTTCCTGGTTGAAGACTGGCTCAGCAGGAAGAGG
AGGGAAGGGGAGGCCCATGAACGTAGGCTCCCTGCAGTGCGCAGCATCAACGGAACATTCCAGGCCGACTTTCCTCTGGGCCCTGCCACCCACGGAGGGACCTACAGATGCTTCGGCTCTTTCCGTGACGCTCCCTACGAGTGGTCAAACTCGAGTGATCCACTGCTTGTTTCCGTCACAGGAAACCCTTCAAATAGTTGGCCTTCACCCACTGAACCAAGCTCCAAAACCGGTAACCCCAGACACCTACAT/GTTCTGATTGGGACCTCAGTGGTCAAAATCCCTTTCACCATCCTCCTCTTCTTTCTCCTTCATCGCTGG
ATGAATAAACAAAGAGGAACCTTCTCAGAAGTGAGTCTGGCCCAGGACCCAAAGCGGCAGCAAAGGAAACCTAAAGGCAATAAAAGCTCCATTTCAGGAACCGAACAGGAAATATTCCAAGTAGAATTAAATCTTCAAAATCCTTCCCTGAATCATCAAGGGATTGATAAAATATATGACTGCCAAGGTTTACTGCCACCTCCAGAGAAG/CTCACTGCCGAGGTCCTAGGAATCATTTGCATTGTCCTGATGGCCACTGTGTTAAAAACAATAGTTCTTATTCCTTTC
GTCCTCACCCTGAGCGACTTCCGCCGAGAGAACGAGGGCTACTATTTCTGCTCGGCCCTGAGCAACTCCATCATGTACTTCAGCCACTTCGTGCCGGTCTTCCTGCCAGCGAAGCCCACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGAT/ATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGC
GCCTCCCACTACTTTGAAAGACACCTGGAGTTCGAGGCCCGGACGCTGTCCCCAGGCCACACCTGGGAGGAGGCCCCCCTGCTGACTCTCAAGCAGAAGCAGGAATGGATCTGCCTGGAGACGCTCACCCCAGACACCCAGTATGAGTTTCAGGTGCGGGTCAAGCCTCTGCAAGGCGAGTTCACGACCTGGAGCCCCTGGAGCCAGCCCCTGGCCTTCAGGACAAAGCCTGCAGCCCTTGGGAAGGACACC/ATTCCGTGGCTCGGCCACCTCCTCGTGGGCCTCAGCGGGGCTTTTGGCTTCATCATCTTAGTGTACTTGCTGATCAACTGCAGG
本発明は、ML NK細胞で有用な細胞内シグナル伝達ドメインを提供する。例えば、NK細胞を使用した他のものは、NK細胞でCD137(4-1BB)を使用できなかったが、驚くべきことに、これらおよび他のものは、ML NK細胞で働き得る。CAR構築物は、1以上の細胞内シグナル伝達ドメインを含み得る。
CD137/41BB(配列番号22)
aaacggggcagaaagaaactcctgtatatattcaaacaaccatttatgagaccagtacaaactactcaagaggaagatggctgtagctgccgatttccagaagaagaagaaggaggatgtgaactg
aaggagaaggagagagagaagagatctatttacagagtcctgggatacacagaaggcacccaataactatagaagtcccatctctaccagtcaacctaccaatcaatccatggatgatacaagagaggatatttatgtcaactatccaaccttctctcgcagaccaaagactagagtttaag
tttctcagggagtattgctaaaatgccaaaaaggaagttgttcaaatgccactcagtatgaggacactggagatctaaaagtgaataatggcacaagaagaaatataagtaataaggacctttgtgcttcgagatctgcagaccagacagtactatgccaatcagaatggctcaaataccaagggaagtgttattggttctctaatgagatgaaaagctggagtgacagttatgtgtattgtttggaaagaaaatctcatctactaatcatacatgaccaacttgaaatggcttttatacagaaaaacctaagacaattaaactacgtatggattgggcttaactttacctccttgaaaatgacatggacttgggtggatggttctccaatagattcaaagatattcttcataaagggaccagctaaagaaaacagctgtgctgccattaaggaaagcaaaattttctctgaaacctgcagcagtgttttcaaatggatttgtcagtattag
agaccagtcccaaggaatttttgacaatttacgaagatgtcaaggatctgaaaaccaggagaaatcacgagcaggagcagacttttcctggaggggggagcaccatctactctatgatccagtcccagtcttctgctcccacgtcacaagaacctgcatatacattatattcattaattcagccttccaggaagtctggatccaggaagaggaaccacagcccttccttcaatagcactatctatgaagtg
attccctatctttgtctactcagcgaacacagggccccgcagagtccgcaaggaacctagagtatgtttcagtgtctccaacgaacaacactgtgtatgcttcagtcactcattcaaacagggaaacagaaatctggacacctagagaaaatgatactatcacaatttactccacaattaatcattccaaagagagtaaacccactttttccagggcaactgcccttgacaatgtcgtgtaa
agtacattgaagagaagaagagagtggacatttgtcgggaaactcctaacatatgcccccattctggagagaacacagagtacgacacaatccctcacactaatagaacaatcctaaaggaagatccagcaaatacggtttactccactgtggaaataccgaaaaag
aaaaggaaaaaacagaggagtcggagaaatgatgaggagctggagacaagagcccacagagtagctactgaagaaaggggccggaagccccaccaaattccagcttcaacccctcagaatccagcaacttcccaacatcctcctccaccacctggtcatcgttcccaggcacctagtcatcgtcccccgcctcctggacaccgtgttcagcaccagcctcagaagaggcctcctgctccgtcgggcacacaagttcaccagcagaaaggcccgcccctccccagacctcgagttcagccaaaacctccccatggggcagcagaaaactcattgtccccttcctctaattaa
atccttgtgatcttctctggaatgttccttgttttcaccctggccggggccctgttcctccatcaacgaaggaaatatagatcaaacaaaggagaaagtcctgtggagcctgcagagccttgtcgttacagctgccccagggaggaggagggcagcaccatccccatccaggaggattaccgaaaaccggagcctgcctgctccccctga
A. ITGB1(配列番号30)
aagcttttaatgataattcatgacagaagggagtttgctaaatttgaaaaggagaaaatgaatgccaaatgggacacgggtgaaaatcctatttataagagtgccgtaacaactgtggtcaatccgaagtatgagggaaaatga
B. ITGB2(配列番号31)
aaggctctgatccacctgagcgacctccgggagtacaggcgctttgagaaggagaagctcaagtcccagtggaacaatgataatccccttttcaagagcgccaccacgacggtcatgaaccccaagtttgctgagagttag
C. ITGB3(配列番号32)
aaactcctcatcaccatccacgaccgaaaagaattcgctaaatttgaggaagaacgcgccagagcaaaatgggacacagccaacaacccactgtataaagaggccacgtctaccttcaccaatatcacgtaccggggcacttaa
aactgcaggaacaccgggccatggctgaagaaggtcctgaagtgtaacaccccagacccctcgaagttcttttcccagctgagctcagagcatggaggagacgtccagaagtggctctcttcgcccttcccctcatcgtccttcagccctggcggcctggcacctgagatctcgccactagaagtgctggagagggacaaggtgacgcagctgctcctgcagcaggacaaggtgcctgagcccgcatccttaagcagcaaccactcgctgaccagctgcttcaccaaccagggttacttcttcttccacctcccggatgccttggagatagaggcctgccaggtgtactttacttacgacccctactcagaggaagaccctgatgagggtgtggccggggcacccacagggtcttccccccaacccctgcagcctctgtcaggggaggacgacgcctactgcaccttcccctccagggatgacctgctgctcttctcccccagtctcctcggtggccccagccccccaagcactgcccctgggggcagtggggccggtgaagagaggatgcccccttctttgcaagaaagagtccccagagactgggacccccagcccctggggcctcccaccccaggagtcccagacctggtggattttcagccaccccctgagctggtgctgcgagaggctggggaggaggtccctgacgctggccccagggagggagtcagtttcccctggtccaggcctcctgggcagggggagttcagggcccttaatgctcgcctgcccctgaacactgatgcctacttgtccctccaagaactccagggtcaggacccaactcacttggtgtag
tataaagttgacttggttctgttctataggcgcatagcggaaagagacgagacactaacagatggtaaaacatatgatgcctttgtgtcttacctgaaagagtgtcatcctgagaataaagaagagtatacttttgctgtggagacgttacccagggtcctggagaaacagtttgggtataagttatgcatatttgaaagagatgtggtgcctggcggagctgttgtcgaggagatccattcactgatagagaaaagccggaggctaatcatcgttctcagccagagttacctgactaacggagccaggcgtgagctcgagagtggactccacgaagcactggtagagaggaagattaagatcatcttaattgagtttactccagccagcaacatcacctttctccccccgtcgctgaaactcctgaagtcctacagagttctaaaatggagggctgacagtccctccatgaactcaaggttctggaagaatcttgtttacctgatgcccgcaaaagccgtcaagccatggagagaggagtcggaggcgcggtctgttctctcagcaccttga
IL12RB1(配列番号35)
aacagggccgcacggcacctgtgcccgccgctgcccacaccctgtgccagctccgccattgagttccctggagggaaggagacttggcagtggatcaacccagtggacttccaggaagaggcatccctgcaggaggccctggtggtagagatgtcctgggacaaaggcgagaggactgagcctctcgagaagacagagctacctgagggtgcccctgagctggccctggatacagagttgtccttggaggatggagacaggtgcaaggccaagatgtga
IL12RB2(配列番号36)
cattacttccagcaaaaggtgtttgttctcctagcagccctcagacctcagtggtgtagcagagaaattccagatccagcaaatagcacttgcgctaagaaatatcccattgcagaggagaagacacagctgcccttggacaggctcctgatagactggcccacgcctgaagatcctgaaccgctggtcatcagtgaagtccttcatcaagtgaccccagttttcagacatcccccctgctccaactggccacaaagggaaaaaggaatccaaggtcatcaggcctctgagaaagacatgatgcacagtgcctcaagcccaccacctccaagagctctccaagctgagagcagacaactggtggatctgtacaaggtgctggagagcaggggctccgacccaaagcccgaaaacccagcctgtccctggacggtgctcccagcaggtgaccttcccacccatgatggctacttaccctccaacatagatgacctcccctcacatgaggcacctctcgctgactctctggaagaactggagcctcagcacatctccctttctgttttcccctcaagttctcttcacccactcaccttctcctgtggtgataagctgactctggatcagttaaagatgaggtgtgactccctcatgctctga
agcctgaagacccatccattgtggaggctatggaagaagatatgggccgtccccagccctgagcggttcttcatgcccctgtacaagggctgcagcggagacttcaagaaatgggtgggtgcacccttcactggctccagcctggagctgggaccctggagcccagaggtgccctccaccctggaggtgtacagctgccacccaccacggagcccggccaagaggctgcagctcacggagctacaagaaccagcagagctggtggagtctgacggtgtgcccaagcccagcttctggccgacagcccagaactcggggggctcagcttacagtgaggagagggatcggccatacggcctggtgtccattgacacagtgactgtgctagatgcagaggggccatgcacctggccctgcagctgtgaggatgacggctacccagccctggacctggatgctggcctggagcccagcccaggcctagaggacccactcttggatgcagggaccacagtcctgtcctgtggctgtgtctcagctggcagccctgggctaggagggcccctgggaagcctcctggacagactaaagccaccccttgcagatggggaggactgggctgggggactgccctggggtggccggtcacctggaggggtctcagagagtgaggcgggctcacccctggccggcctggatatggacacgtttgacagtggctttgtgggctctgactgcagcagccctgtggagtgtgacttcaccagccccggggacgaaggacccccccggagctacctccgccagtgggtggtcattcctccgccactttcgagccctggaccccaggccagctaa
cccctgagcatgcatcagcagcagcagctccagcaccagcagttccagaaggaactggagaagatccagctcctgcagcagcagcagcagcagctgcccttccacccacctggagacacggctcaggacggcgagctcctggacacgtctggcccgtactcagagagctcgggcaccagcagccccagcacgtcccccagggcctccaaccactcgctctgctccggcagctctgcctccaaggctggcagcagcccctccctggaacaagacgatggagatgaggaaaccagcgtggtgatagttgggaaaatttccttctgtcccaaggatgtcctgggccatggagctgagggcacaattgtgtaccggggcatgtttgacaaccgcgacgtggccgtgaagaggatcctccccgagtgttttagcttcgcagaccgtgaggtccagctgttgcgagaatcggatgagcacccgaacgtgatccgctacttctgcacggagaaggaccggcaattccagtacattgccatcgagctgtgtgcagccaccctgcaagagtatgtggagcagaaggactttgcgcatctcggcctggagcccatcaccttgctgcagcagaccacctcgggcctggcccacctccactccctcaacatcgttcacagagacctaaagccacacaacatcctcatatccatgcccaatgcacacggcaagatcaaggccatgatctccgactttggcctctgcaagaagctggcagtgggcagacacagtttcagccgccgatctggggtgcctggcacagaaggctggatcgctccagagatgctgagcgaagactgtaaggagaaccctacctacacggtggacatcttttctgcaggctgcgtcttttactacgtaatctctgagggcagccacccttttggcaagtccctgcagcggcaggccaacatcctcctgggtgcctgcagccttgactgcttgcacccagagaagcacgaagacgtcattgcacgtgaattgatagagaagatgattgcgatggatcctcagaaacgcccctcagcgaagcatgtgctcaaacacccgttcttctggagcctagagaagcagctccagttcttccaggacgtgagcgacagaatagaaaaggaatccctggatggcccgatcgtgaagcagttagagagaggcgggagagccgtggtgaagatggactggcgggagaacatcactgtccccctccagacagacctgcgtaaattcaggacctataaaggtggttctgtcagagatctcctccgagccatgagaaataagaagcaccactaccgggagctgcctgcagaggtgcgggagacgctggggtccctccccgacgacttcgtgtgctacttcacatctcgcttcccccacctcctcgcacacacctaccgggccatggagctgtgcagccacgagagactcttccagccctactacttccacgagcccccagagccccagcccccagtgactccagacgccctctga
所望により、シグナル伝達を増幅するために細胞外シグナル伝達ドメインをCAR構築物に組み込み得る。細胞外シグナル伝達ドメインは、CD8ヒンジなどのヒンジ領域にクローン化され得るが、標的に基づき、選択され得る。
次の定義および方法は、本発明をより良好に定義し、本発明の実施に際して当業者への指針となるために提供する。特に断らない限り、用語は、関連分野の当業者による一般的使用に従うと理解される。
ここに記載する薬剤および組成物は、例えば、引用により全体として本明細書に包含させるRemington's Pharmaceutical Sciences (A.R. Gennaro, Ed.), 21st edition, ISBN: 0781746736 (2005)に記載のとおり、1以上の薬学的に許容される担体または添加物を使用して、何らかの慣用の方法により製剤化され得る。このような製剤は、対象への適切な投与のための形態を提供するよう、適当な量の担体と共に、精製された形態であり得るここに記載する生物学的活性剤を治療有効量で含む。
また提供されるのは、NK細胞ベースの治療(例えば、遺伝子修飾NK細胞を使用)の治療有効量の投与が必要である対象における、増殖性疾患、障害または状態、感染性疾患または免疫障害を処置する方法である。開示されるNK細胞ベースの治療を、癌(例えば、免疫療法薬物として)、自己免疫疾患(例えば、B細胞枯渇のための処置)または感染性疾患の処置剤として使用し得る。
本発明のある態様は、対象に直接投与される、NK細胞(例えば、CARML NK細胞、修飾NK細胞、予め活性化されたNK細胞、NKG2A遮断NK細胞、予め活性化されたおよびNKG2A遮断NK細胞)を提供する。
次の実施例は、CARML NK細胞、CARML NK細胞を産生する方法およびCARML NK細胞の特徴づけを記載する。
標的細胞で発現されるCD19、CD22およびCD123抗原を標的とするCAR構築物を有するCARML NK細胞が産生され得ることが示された(例えば、図1、図12参照)。
CARML NK細胞が、抗原特異的標的により強固な応答を示すことが示された(例えば、図2、図3、図6、図9参照)。CARML NK細胞を、図1、図6および図8に示すとおり産生した。
細胞をRaji(CD19+腫瘍細胞株)で6時間刺激し、フローサイトメトリーにより評価した。データは、CARML NK細胞がCD19+Raji標的に強固におよび特異的に応答したことを示した(例えば、図3、図6参照)。
CD19-CARML NK細胞が腫瘍細胞株および原発濾胞性リンパ腫標的に対し増強された抗原(CD19)特異的応答を示すことが示された(例えば、図7参照)。
CD33-CARML NK細胞が、腫瘍細胞株に対して抗原(CD33)特異的に増強された応答を示すことも示された(例えば、図9参照)。
CD19-CAR(IL2Rb)-ML NK細胞がCD19+Raji標的存在下でpSTAT-5シグナル伝達増強を示すことも示された(例えば、図11参照)。
本試験は、CD19特異的ML NK細胞が、CD19+Raji担持マウスにおいて、インビボで拡大し、腫瘍負荷を制御することを示した(例えば、図8参照)。
抗腫瘍応答、サイトカイン産生、細胞毒性、増殖、持続を最適化するための記憶様NK細胞特異的遺伝子修飾の戦略を、図4、図5および図12に記載する。CARをML NK細胞を特異的に刺激させるための設計の論理的根拠が有効であることが示された。例えば、NKG2D発現はML NK細胞で増加し、NKG2D TMドメインの包含は、CARML NK細胞におけるシグナル伝達を増強させる。
種々のシグナル伝達ドメインを有するCD19、CD33およびCD123 CARML NK細胞が、ここに記載するプロトコールを使用して産生された(see 例えば、図1B、図6B、図8、図12)。
ここで、初代NK細胞を末梢血単核細胞(PBMC)から精製した。PBMCは、円形の核を有するあらゆる末梢血細胞である。これらの細胞は、リンパ球(T細胞、B細胞、NK細胞)および単球からなり、一方赤血球および血小板に核はなく、顆粒球(好中球、好塩基球および好酸球)は多葉性核を有する。他の産物は幹細胞または細胞株由来であった。
サイトカイン添加の順番がML NK細胞産生に重要であることが判明した。-1日に、CIML活性化サイトカイン、IL-12/15/18を加えた。0日に、サイトカインを洗い流し、細胞の培養をアッセイの残り期間IL-15中で継続した。
ここで、CARを、レンチウイルスを使用して導入した。単にあらゆるウイルス構築物が働かないだけでなく、現在T細胞に使用される他のウイルス粒子を使用して、CARはML NK細胞に導入できないことが発見された。
他の方法で使用したポリブレンがNK細胞を殺すことも判明した。すなわち、慣用的に使用されるポリブレンは、形質導入中使用しない。
キメラ抗原受容体(CAR)をするカセットを、MNDレンチウイルス骨格に組み込んで、レンチウイルスベクターを産生した。レンチウイルス上清を産生するために、293T細胞を、カルシウムクロライドトランスフェクション試薬を使用して、レンチウイルスベクター、pMND-G、pMND-LgおよびpMDN-REVと共トランスフェクトした。レンチウイルスを含む上清を24~48時間後に回収し、超遠心分離を使用して濃縮した。形質導入のために、精製サイトカイン活性化(IL-12/15/18)NK細胞を、50ng/mL IL-15添加完全培養培に播種した。ウイルス上清を細胞に加え、2000rpmで90分間、室温でスピンフェクトした。細胞を、37℃で5%CO2中、インキュベートした。ウイルス形質導入有効性を最大化するために、細胞を1日目および2日目にスピンフェクトした。次いで、細胞を洗浄し、すぐに使用するかまたは1ng/mL IL-15添加完全培地で培養した。最大ベクター発現が7日目までに期待される。
図1A、図1B、図6Aおよび図6Bに記載するとおり、NK細胞を正常ドナーPBMCから精製し、IL-12/15/18中インキュベートした。サイトカインを洗い流し、次いで細胞を高用量IL-15中でインキュベートし、CARレンチウイルスで2回形質導入した。細胞を休息させ(インビボまたはインビトロ)、エフェクター機能の増強について評価した。
本実施例は、(A)ハプロ/同種CARML NK細胞または(B)自己CARML NK細胞での患者処置のための臨床的調製を記載する(例えば、図13参照)。
アフェレーシスを実施し、NK細胞を精製し、IL-12/IL-15/IL-18で約12時間活性化させる。NK細胞を洗浄し、約2日にわたり2回CARレンチウイルスとスピンフェクトする。細胞を洗浄し、患者に約107細胞/kgで注入する。ハプロ/アロ設定で細胞はrhIL-2により支持され、自己設定で細胞はIL-15により支持される。
Claims (48)
- キメラ抗原受容体構築物(CAR構築物)であって、
(i)疾患関連抗原に対するターゲティング抗体フラグメント;
(ii)膜貫通ドメイン;および
(iii)少なくとも1つの細胞内シグナル伝達ドメイン
を含み、
記憶様ナチュラルキラー(ML NK)細胞で発現されるかまたは機能することができる、CAR構築物。 - 疾患関連抗原はが、CD19、CD33、CD123、CD20、BCMA、メソテリン、EGFR、CD3、CD4 BAFF-R、EGFR、HER2、gp120またはgp41からなる群から選択される、請求項1のCAR構築物。
- 膜貫通ドメインが、NKG2D、FcγRIIIa、NKp44、NKp30、NKp46、actKIR、NKG2C、CD8αおよびIL15Rbからなる群から選択される、請求項1のCAR構築物。
- 少なくとも1つの細胞内シグナル伝達ドメインが、CD137/41BB、DNAM-1、NKp80、2B4、NTBA、CRACC、CD2、CD27、1以上のインテグリン類、IL-15R、IL-18R、IL-12R、IL-21R、IRE1aおよびこれらの組み合わせからなる群から選択される、請求項1のCAR構築物。
- 少なくとも1つの細胞内シグナル伝達ドメインが膜貫通アダプターである、請求項1のCAR構築物。
- 膜貫通アダプターまたはヒンジをさらに含む、請求項1のCAR構築物。
- 膜貫通アダプターが、FceR1γ、CD3ζ、DAP12、DAP10およびこれらの組み合わせからなる群から選択される、請求項5または6のCAR構築物。
- 1種以上のインテグリン類が、ITGB1、ITGB2、ITGB3およびこれらの組み合わせからなる群から選択される、請求項4のCAR構築物。
- 疾患関連抗原に対するターゲティング抗体フラグメントが、
(i)配列番号1のアミノ酸配列を含む抗CD19 scFv;
(ii)配列番号2のアミノ酸配列を含む抗CD33 scFv;および
(iii)配列番号3のアミノ酸配列を含む抗CD123 scFv
からなる群から選択されるscFvを含む、請求項1のCAR構築物。 - 膜貫通ドメインが、
配列番号5のアミノ酸配列を含むNKG2D;
配列番号7のアミノ酸配列を含むFcγRIIIa;
配列番号9のアミノ酸配列を含むNKp44;
配列番号11のアミノ酸配列を含むNKp30;
配列番号13のアミノ酸配列を含むNKp46;
配列番号15のアミノ酸配列を含むactKIR;
配列番号17のアミノ酸配列を含むNKG2C;
配列番号19のアミノ酸配列を含むCD8α;および
配列番号21のアミノ酸配列を含むIL15Rb
からなる群から選択される、請求項3のCAR構築物。 - ヒンジが
配列番号4のアミノ酸配列を含むNKG2D;
配列番号6のアミノ酸配列を含むFcγRIIIa;
配列番号8のアミノ酸配列を含むNKp44;
配列番号10のアミノ酸配列を含むNKp30;
配列番号12のアミノ酸配列を含むNKp46;
配列番号14のアミノ酸配列を含むactKIR;
配列番号16のアミノ酸配列を含むNKG2C;
配列番号18のアミノ酸配列を含むCD8α;および
配列番号20のアミノ酸配列を含むIL15Rb
からなる群から選択される、請求項6のCAR構築物。 - 少なくとも1つの細胞内シグナル伝達ドメインが、
配列番号22のアミノ酸配列を含むCD137/41BB;
配列番号23のアミノ酸配列を含むDNAM-1;
配列番号24のアミノ酸配列を含むNKp80;
配列番号25のアミノ酸配列を含む2B4;
配列番号26のアミノ酸配列を含むNTBA;
配列番号27のアミノ酸配列を含むCRACC;
配列番号28のアミノ酸配列を含むCD2;
配列番号29のアミノ酸配列を含むCD27;
インテグリン類;
配列番号30のアミノ酸配列を含むITGB1;
配列番号31のアミノ酸配列を含むITGB2または配列番号32のアミノ酸配列を含むITGB3;
配列番号33のアミノ酸配列を含むIL15RB;
配列番号34のアミノ酸配列を含むIL18R;
配列番号35のアミノ酸配列を含むIL12RB1および配列番号36のアミノ酸配列を含むIL12RB2であるIL12R;
配列番号37のアミノ酸配列を含むIL21R;
配列番号38のアミノ酸配列を含むIRE1a;および
これらの組み合わせからなる群から選択される、請求項1のCAR構築物。 - 請求項1のCAR構築物を含む、記憶様ナチュラルキラー(ML NK)細胞。
- キメラ抗原受容体記憶様ナチュラルキラー(CARML NK)細胞を産生する方法であって、
NK細胞、IL-12/15/18およびIL-15を含む活性化サイトカインを準備し;
NK細胞および活性化サイトカインを、サイトカイン活性化記憶様(ML)NK細胞を形成するのに十分な時間接触させ;
キメラ抗原受容体(CAR)を、ウイルスベクターを介して、サイトカイン活性化ML NK細胞に、CAR形質導入ML NK細胞をもたらすよう、CARをサイトカイン活性化ML NK細胞にウイルスにより形質導入するのに十分な時間、IL-15存在下で形質導入し;そして
CAR発現ML NK(CARML NK細胞)を形成するのに十分な時間、CAR形質導入ML NK細胞をIL-15存在下でインキュベートすること
を含む、方法。 - NK細胞が末梢血単核細胞(PBMC)から単離された、請求項14の方法。
- サイトカイン活性化NK細胞を形成させるのに十分な時間が約8~約24時間、約12時間または約16時間である、請求項14の方法。
- CARをML NK細胞にウイルスにより形質導入するのに十分な時間が約12時間~約24時間である、請求項14の方法。
- CAR発現ML NK細胞(CARML NK細胞)を形成させるのに十分な時間が少なくとも約3日間~約8日間または約7日間である、請求項14の方法。
- キメラ抗原受容体(CAR)を含むウイルスベクターがCARレンチウイルスである、請求項14の方法。
- ウイルスベクターがpMND-G、pMND-Lg、pMDN-REVおよびこれらの組み合わせからなる群から選択されるレンチウイルスベクターである、請求項14の方法。
- キメラ抗原受容体(CAR)の、ウイルスベクターを介するサイトカイン活性化ML NK細胞への形質導入がポリブレンの非存在下で実施される、請求項14の方法。
- 請求項1~13の何れかのCAR構築物を含む、請求項14~21の何れかの方法により製造されたキメラ抗原受容体記憶様ナチュラルキラー(CARML NK)細胞。
- 処置を必要とする対象における疾患に対する免疫応答を誘導する方法であって、
キメラ抗原受容体記憶様(CARML)NK細胞を対象に投与することを含み、
ここで、CARML NK細胞が
(i)疾患関連抗原に対するターゲティング抗体フラグメント;
(ii)膜貫通ドメイン;および
(iii)少なくとも1つの細胞内シグナル伝達ドメイン
を含むキメラ抗原受容体(CAR)を含むものである、方法。 - 疾患関連抗原がCD19、CD33、CD123、CD20、BCMA、メソテリン、EGFR、CD3、CD4 BAFF-R、EGFR、HER2、gp120またはgp41からなる群から選択される、請求項23の方法。
- 膜貫通ドメインがNKG2D、FcγRIIIa、NKp44、NKp30、NKp46、actKIR、NKG2C、CD8αおよびIL15Rbからなる群から選択される、請求項23の方法。
- 少なくとも1つの細胞内シグナル伝達ドメインがCD137/41BB、DNAM-1、NKp80、2B4、NTBA、CRACC、CD2、CD27、1種以上のインテグリン類、IL-15R、IL-18R、IL-12R、IL-21R、IRE1aおよびこれらの組み合わせからなる群から選択される、請求項23の方法。
- 少なくとも1つの細胞内シグナル伝達ドメインが膜貫通アダプターである、請求項23の方法。
- 膜貫通アダプターをさらに含む、請求項23の方法。
- 膜貫通アダプターがFceR1γ、CD3ζ、DAP12、DAP10およびこれらの組み合わせからなる群から選択される、請求項27または28の何れかの方法。
- 1種以上のインテグリン類がITGB1、ITGB2、ITGB3およびこれらの組み合わせからなる群から選択される、請求項26の方法。
- 疾患関連抗原に対するターゲティング抗体フラグメントが
(i)配列番号1のアミノ酸配列を含む抗CD19 scFv;
(ii)配列番号2のアミノ酸配列を含む抗CD33 scFv;および
(iii)配列番号3のアミノ酸配列を含む抗CD123 scFv
からなる群から選択されるscFvを含む、請求項23の方法。 - 膜貫通ドメインが
配列番号5のアミノ酸配列を含むNKG2D;
配列番号7のアミノ酸配列を含むFcγRIIIa;
配列番号9のアミノ酸配列を含むNKp44;
配列番号11のアミノ酸配列を含むNKp30;
配列番号13のアミノ酸配列を含むNKp46;
配列番号15のアミノ酸配列を含むactKIR;
配列番号17のアミノ酸配列を含むNKG2C;
配列番号19のアミノ酸配列を含むCD8α;および
配列番号21のアミノ酸配列を含むIL15Rb
からなる群から選択される、請求項25の方法。 - 配列番号4のアミノ酸配列を含むNKG2D;
配列番号6のアミノ酸配列を含むFcγRIIIa;
配列番号8のアミノ酸配列を含むNKp44;
配列番号11のアミノ酸配列を含むNKp30;
配列番号12のアミノ酸配列を含むNKp46;
配列番号14のアミノ酸配列を含むactKIR;
配列番号16のアミノ酸配列を含むNKG2C;
配列番号18のアミノ酸配列を含むCD8α;および
配列番号20のアミノ酸配列を含むIL15Rb
からなる群から選択されるヒンジをさらに含む、請求項23の方法。 - 少なくとも1つの細胞内シグナル伝達ドメインが
配列番号22のアミノ酸配列を含むCD137/41BB;
配列番号23のアミノ酸配列を含むDNAM-1;
配列番号24のアミノ酸配列を含むNKp80;
配列番号25のアミノ酸配列を含む2B4;
配列番号26のアミノ酸配列を含むNTBA;
配列番号27のアミノ酸配列を含むCRACC;
配列番号28のアミノ酸配列を含むCD2);
配列番号29のアミノ酸配列を含むCD27);
インテグリン類、配列番号30のアミノ酸配列を含むITGB1、配列番号31のアミノ酸配列を含むITGB2および配列番号32のアミノ酸配列を含むITGB3;
配列番号33のアミノ酸配列を含むIL15RB;
配列番号34のアミノ酸配列を含むIL18R;
配列番号35のアミノ酸配列を含むIL12RB1および配列番号36のアミノ酸配列を含むIL12RB2であるIL12R;
配列番号37のアミノ酸配列を含むIL21R;
配列番号38のアミノ酸配列を含むIRE1a;およびこれらの組み合わせ
からなる群から選択される、請求項23の方法。 - CAR構築物が記憶様ナチュラルキラー(ML NK)細胞で発現または機能できる、請求項23の方法。
- CARML NK細胞が抗原特異的標的に対する免疫応答を誘導する、請求項23の方法。
- CARML NK細胞が腫瘍負荷を軽減する、請求項23の方法。
- 疾患関連抗原に対するターゲティング抗体フラグメントが疾患関連抗原に対する一本鎖可変フラグメント(scFv)を含む、請求項23の方法。
- 対象が疾患関連抗原がある疾患を有する、請求項23の方法。
- 抗原がB細胞抗原であり、疾患が血液癌、自己免疫疾患および免疫系障害からなる群から選択される、請求項23の方法。
- 抗原が腫瘍関連抗原(TAA)であり、疾患が癌である、請求項23の方法。
- CARML NK細胞が、対照と比較して、抗原標的またはエピトープに対する機能的応答が増強している、請求項23の方法。
- 対照がCARを伴わないML NK細胞、ScFvを伴わないMLNK細胞、CARを伴うNK細胞、CAR scFvを伴うNK細胞、標的と関連しないscFvを含むML NKまたは標的と関連しないscFvを含むNKである、請求項42の方法。
- 対象が癌、自己免疫状態または感染性疾患(例えば、細菌、ウイルス)を有する、請求項23の方法。
- 処置を必要とする対象にCARML NK細胞を投与することを含む、方法であって、
対象またはドナーからNK細胞を単離し;
請求項14のCARML NK細胞を産生し;そして
対象にCARML NK細胞の治療有効量を投与する
ことを含む、方法。 - CARML NK細胞の治療有効量が約107細胞/kgである、請求項45の方法。
- rhIL-2またはIL-15が対象に投与される、請求項45の方法。
- キメラ抗原受容体構築物(CAR構築物)であって、
(i)配列番号1を含む抗CD19 scFv、配列番号2を含む抗CD33 scFvまたは配列番号3を含む抗CD123 scFv;
(ii)配列番号19を含むCD8a膜貫通ドメイン、配列番号11を含むNKp30膜貫通ドメインまたは配列番号5を含むNKG2D膜貫通ドメイン;および
(iii)配列番号22を含むCD137細胞内シグナル伝達ドメイン、配列番号33を含むIL-15R細胞内シグナル伝達ドメインまたは配列番号25を含む2B4細胞内シグナル伝達ドメイン
を含み、
記憶様ナチュラルキラー(ML NK)細胞で発現されるかまたは機能することができる、CAR構築物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862756294P | 2018-11-06 | 2018-11-06 | |
US62/756,294 | 2018-11-06 | ||
US201962788440P | 2019-01-04 | 2019-01-04 | |
US62/788,440 | 2019-01-04 | ||
PCT/US2019/060005 WO2020097164A1 (en) | 2018-11-06 | 2019-11-06 | Chimeric antigen receptor memory-like (carml) nk cells and methods of making and using same |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022512922A true JP2022512922A (ja) | 2022-02-07 |
JPWO2020097164A5 JPWO2020097164A5 (ja) | 2022-11-14 |
Family
ID=70612473
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021524069A Pending JP2022512922A (ja) | 2018-11-06 | 2019-11-06 | キメラ抗原受容体記憶様(carml)nk細胞ならびにその産生および使用方法 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220073585A1 (ja) |
EP (1) | EP3876961A4 (ja) |
JP (1) | JP2022512922A (ja) |
KR (1) | KR20210090220A (ja) |
CN (1) | CN113423409A (ja) |
AU (1) | AU2019377461A1 (ja) |
CA (1) | CA3117206A1 (ja) |
IL (1) | IL282850A (ja) |
SG (1) | SG11202104287RA (ja) |
WO (1) | WO2020097164A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4251741A1 (en) | 2020-11-30 | 2023-10-04 | CRISPR Therapeutics AG | Gene-edited natural killer cells |
CN117062611A (zh) * | 2021-01-26 | 2023-11-14 | 惠和生物技术(上海)有限公司 | 嵌合抗原受体(car)构建体和表达car构建体的nk细胞 |
EP4293041A1 (en) * | 2021-02-10 | 2023-12-20 | Cure Genetics Co., Limited | Amplification enhancer and use thereof |
WO2023183853A1 (en) | 2022-03-22 | 2023-09-28 | WUGEN, Inc. | Hybrid promoters, vectors containing same and methods of use |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
KR20140060541A (ko) * | 2011-09-16 | 2014-05-20 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암을 치료하기 위한 rna 조작된 t 세포 |
EP2948544A4 (en) * | 2013-01-28 | 2016-08-03 | St Jude Childrens Res Hospital | CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES |
KR102612313B1 (ko) * | 2014-07-21 | 2023-12-12 | 노파르티스 아게 | 인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료 |
JP6849600B6 (ja) * | 2015-01-29 | 2021-06-30 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | キメラ抗原受容体、組成物及び方法 |
AU2018240556A1 (en) * | 2017-03-24 | 2019-10-10 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-CD33 immunotherapy |
-
2019
- 2019-11-06 JP JP2021524069A patent/JP2022512922A/ja active Pending
- 2019-11-06 AU AU2019377461A patent/AU2019377461A1/en active Pending
- 2019-11-06 CN CN201980088089.2A patent/CN113423409A/zh active Pending
- 2019-11-06 CA CA3117206A patent/CA3117206A1/en active Pending
- 2019-11-06 KR KR1020217017370A patent/KR20210090220A/ko active Search and Examination
- 2019-11-06 EP EP19882787.5A patent/EP3876961A4/en active Pending
- 2019-11-06 WO PCT/US2019/060005 patent/WO2020097164A1/en unknown
- 2019-11-06 SG SG11202104287RA patent/SG11202104287RA/en unknown
- 2019-11-06 US US17/291,959 patent/US20220073585A1/en active Pending
-
2021
- 2021-05-02 IL IL282850A patent/IL282850A/en unknown
Also Published As
Publication number | Publication date |
---|---|
SG11202104287RA (en) | 2021-05-28 |
US20220073585A1 (en) | 2022-03-10 |
KR20210090220A (ko) | 2021-07-19 |
CN113423409A (zh) | 2021-09-21 |
EP3876961A4 (en) | 2023-01-25 |
EP3876961A1 (en) | 2021-09-15 |
IL282850A (en) | 2021-06-30 |
WO2020097164A1 (en) | 2020-05-14 |
AU2019377461A1 (en) | 2021-05-27 |
CA3117206A1 (en) | 2020-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7438988B2 (ja) | Bcmaキメラ抗原受容体及びその使用 | |
KR20220104217A (ko) | Cd19 및 cd22 키메라 항원 수용체 및 이의 용도 | |
JP2022512922A (ja) | キメラ抗原受容体記憶様(carml)nk細胞ならびにその産生および使用方法 | |
US11639496B2 (en) | Reducing fratricide of immune cells expressing NKG2D-based receptors | |
JP7475088B2 (ja) | ヒトメソセリンを特異的に認識する細胞表面分子、il-7、及びccl19を発現する免疫担当細胞 | |
CN114174495A (zh) | 肿瘤浸润淋巴细胞疗法及其用途 | |
JP2020530993A (ja) | キメラ抗原受容体または改変tcrを発現し、選択的に発現されるヌクレオチド配列を含む細胞 | |
JP2022509017A (ja) | 抗ptk7免疫細胞癌療法 | |
JP2022023136A (ja) | T細胞の拡張及び活性化の方法 | |
CN111902532A (zh) | 用于癌症治疗的精氨酸酶抑制 | |
JP2024513522A (ja) | Nk細胞およびher2標的抗体を用いた癌治療 | |
US20230092787A1 (en) | Car t cells targeting the integrin alphav beta3 exhibit robust anti-tumor responses against gliomas and other solid tumor malignancies | |
JP2023536820A (ja) | 二重car-t細胞 | |
JPWO2018110374A1 (ja) | 殺細胞効果を有するキメラ抗原受容体遺伝子改変リンパ球 | |
US20240075141A1 (en) | Chimeric receptor constructs for nk cells | |
WO2023234297A1 (ja) | がんを処置するための組成物 | |
US20230330228A1 (en) | Hybrid promoters, vectors containing same and methods of use | |
US20240173407A1 (en) | Generation of cd3 expressing immune cells for use in conjunction with cd3 binding bispecific targeting agents | |
US20230242666A1 (en) | Methods and Compositions for the Reduction of Chimeric Antigen Receptor Tonic Signaling | |
RU2776890C9 (ru) | Клеточная терапия, основанная на улучшенных клетках-естественных киллерах | |
WO2024059821A2 (en) | Car t cell compositions for treatment of cancer | |
JP2024510898A (ja) | Ror1を標的とするキメラ抗原受容体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221104 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221104 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231003 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231219 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240301 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240402 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20240502 |